Phencyclidine residues were found in the brains of rat pups of mothers dosed with this drug during pregnancy. These levels were significant at times after dosing when maternal levels of phencyclidine in serum or brain were low or undetectable. The persistence of this compound in fetal serum was also not prolonged. Maternal ingestion of PCP for a relatively brief time may result in an extended exposure of the developing nervous system.
Phencyclidine (PCP, 'angel dust'), 1-(1-phenylcyclohexyl) piperidine was originally developed as an anaesthetic, but its use was discontinued in view of undesirable side-effects 9 • It is, however, a widely used drug of abuse 2 , perhaps due to its ease of manufacture. Some hospitals report that, a significant proportion (40-45%) of emergency drug misuse admissions are related to this compound 1 . Its use among pregnant women has led to the birth of offspring exhibiting behavioral abnormalities including temporary rigidity or irritability and revealing PCP in their blood and urine 5 . These findings were occasionally made when the mother's urine contained no detectable PCP and when mothers stated that the use of PCP had been discontinued for at least 3 months prior to childbirth 4 • 6 • 12 . This raised the possibility of a chronic retention of PCP by feti during gestation. A study using rats was initiated in order to further investigate such a concept.
Pregnant rats, initially weighing 235-250 g (Sprague-Dawley CD strain) were maintained in 4 groups of 6 at 20 ± 2 °C, with free access to food and water.
Each of the 6 rats in the 4 experimental groups which received 5 mg PCP/kg b. wt. (dissolved in 10% methanol in 0.9% saline injected at 1 ml/kg) injected s.c. in the scruff of the neck on 3 consecutive days. The treated dams showed some lack of motor coordination 10-30 min after dosing and subsequently became lethargic (30-60 min). PCP (Alltech, Deerfield, IL) was >98% pure.
Postconception days of injection were 9, 10, 11, (Group I), 12, 13, 14 (Group II), 15, 16, 17 (Group III) and 18, 19, 20 (Group IV). A control of 8 mothers received corresponding injections of 10% methanol/saline. Two control rats were injected at each of the times corresponding to each experimental group. No physical differences were detected between any groups. On gestational day 22, all mothers and their young were killed, maternal and infant serum being obtained from clotted blood. Brains were collected and rapidly frozen after weighing offspring and their brains. No gross physical or behavioral abnormalities were observed in the offspring as judged by coarse, visual inspection of external features and motility relative to controls. The number of live infants born to a mother, and their brain and body weights did not dif- fer significantly between groups (data not shown).
The tissues collected from the progeny of each mother were pooled and treated as n = 1. The concentration of PCP in brains and serum was determined by. radioimmunoassay using a commercially manufactured antibody (Immunalysis, Glendale, CA). This antibody showed no major cross-reactivity with PCP glucuronides. The extent of interaction with most PCP metabolites 5 is unknown but aromatic hydroxylated PCP derivatives exhibit complete cross-reactivity. Standard amounts of PCP were added to blood, or to brain homogenates, and concentration curves were developed from these standards. The limit of sensitivity of this method corresponded to a concentration of 0.2 ng PCP/ml blood. These curves were linear over the range of concentrations used. The only rats showing PCP in circulating blood were in Group IV (Table I ). The examination of brain tissue revealed significant amounts of PCP in 3 progeny groups. The agent was detectable only in Group IV mothers (Table I ). The cerebral concentration of PCP in the offspring of Group IV was approximately 16 times the corresponding serum level and 11 times the level in maternal brains. Maternal brain levels in Group IV were also greater than the corresponding serum levels of PCP. The relatively large variability of the PCP levels found in the brain may be a causal factor in the reported unpredictability of the human response to PCP 8 • Several possible explanations could underlie these data. The rate of metabolism or efflux of PCP from fetal brain could be very low, or the uptake of PCP from the bloodstream by fetal brain could be greater than uptake by maternal brain. In an attempt to distinguish between these alternatives, pregnant rats were injected a single time with PCP (5 mg/kg) on day 20 of gestation. Thirty min later, rats were killed and PCP levels in serum and brain of mothers and embryos determined. This time point was selected because of a report describing maximal PCP uptake in mouse brain and mouse feti to occur within 15-30 min after drug administration 11 • Furthermore, behavioral abnormality in our injected rats was seen between 10 and 30 min after PCP dosing. At this short exposure time, the fetal serum level of PCP was significantly higher than the corresponding maternal concentration (Table II) . This may be due to the lack of conjugative and degradative hepatic microsomal enzymes in the fetus, and is in accord with a previous study using pigs 3 . The maternal serum PCP levels were not much greater than those found for humans after a non-fatal overdose (49-171 ng/ml) 10 • The fetal brain level of PCP was similar to the serum level, implying the absence of a barrier to the free diffusion of PCP. In contrast the adult brain of the mothers had only 2% of the PCP concentration of maternal serum. This suggests a considerable initial exclusion of this amphiphilic cationic compound by the more highly developed adult blood-brain barrier and is in contrast to a study where PCP was i. p. administered to adult male mice 5 . A more detailed kinetic study is planned together with a behavioral analysis of offspring from dosed mothers.
The implications of this study point toward a potential hazard of prolonged exposure to PCP of infants from mothers using this drug during pregnancy.
